Pharmaceuticals

A large study alleviates concerns that Celebrex boosts the risk for heart attacks and strokes as much as Vioxx. But the findings raise some concerns about prescription doses of ibuprofen and naproxen.

The Justice Department is investigating whether several companies colluded to raise prices of generic drugs. A report suggests a lawsuit could be filed this year.

The Auvi-Q epinephrine injector was pulled from the market in 2015 because of quality concerns. Now, the drug's maker says the problems have been solved and Auvi-Q will be available again in 2017.

Months after a man died in a botched clinical trial in France, the company that ran it has opened a big research facility in New Jersey, where as many as 50 clinical trials could be done each year.

About 27 percent of Food and Drug Administration reviewers who approved hematology-oncology drugs from 2001 through 2010 left to work for the industry they previously regulated, an analysis found.

The Food and Drug Administration approved a muscular dystrophy drug despite deeply flawed evidence. Was the decision a dangerous precedent or flexible pragmatism reflecting patients' values?

Researchers analyzing recent drug spending in the U.S. say that high-priced drugs for rare diseases aren't having a widespread or significant effect on overall health care spending.

Four years after user fees were imposed to speed up the review of generic drug applications by the Food and Drug Administration, more than 4,000 generics remain in limbo.